Femoral Nerve Blockade 7.5 ml of 1% Lidocaine: US Guidance Versus US Guidance With Electrical Stimulation of Peripheral Nerves (Influence of the Femoral Nerve Blockade on the Effectiveness of Small Doses of Local Anesthetic.). (EPBwEPN)

Last updated: August 25, 2022
Sponsor: Mogilev Regional Clinical Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Anesthesia (Local)

Treatment

N/A

Clinical Study ID

NCT05209711
7.5ml femoral nerve
  • Ages 18-90
  • All Genders

Study Summary

In modern anesthesiology, peripheral nerve blocks are performed using ultrasound control and electrical stimulation of peripheral nerves (PEN), or only ultrasound control or only EPN. The most effective methods are with the use of ultrasound control. Until now, the effectiveness of the femoral nerve blockade, performed only under ultrasound control without EPN, in comparison with the blockade of the femoral nerve performed under ultrasound control with EPN, has not been established.

There is no data on how the effectiveness of the blockade of the femoral nerve with small doses of lidocaine is influenced by the method of performing the blockade: under ultrasound control versus ultrasound control with electrostimulation of the nerve.

Research hypothesis: the blockade of the femoral nerve (7.5 ml 1%lidocaine -Minimum Effective Dose - previously established ) performed only under ultrasound control has the same effectiveness as the blockade performed under the ultrasound control with EPN.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • indication requiring anesthesia maintenance;
  • patient's written consent about the type of anesthesia and possible complications ofregional anesthesia

Exclusion

Exclusion Criteria:

  • patient's refusal of application for the proposed form of anesthesia;
  • patients younger than 18 years;
  • patients weighing less than 50 kg;
  • a physical status score of more than 3 determined by the American Society of --Anesthesiologists (ASA);
  • a history of allergic reactions to the drugs used;
  • coagulopathies;
  • infections of the skin at the injection site;
  • neurological or neuromuscular diseases;
  • severe liver diseases or kidney failures;
  • an inability to cooperate with the patient.

Study Design

Total Participants: 40
Study Start date:
February 01, 2022
Estimated Completion Date:
October 31, 2022

Connect with a study center

  • Mogilev Regional Clinical Hospital

    Mogilev, 212026
    Belarus

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.